Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients

BACKGROUND: Tumor response characteristics using immune-related RECIST1.1 (irRECIST1.1) in advanced non-small-cell lung cancer (NSCLC) patients treated with nivolumab monotherapy in the clinical setting have not been previously described with a direct comparison with the assessments according to the...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishino, Mizuki, Ramaiya, Nikhil H., Chambers, Emily S., Adeni, Anika E., Hatabu, Hiroto, Jänne, Pasi A., Hodi, F. Stephen, Awad, Mark M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5168591/
https://www.ncbi.nlm.nih.gov/pubmed/28018599
http://dx.doi.org/10.1186/s40425-016-0193-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5168591/
https://www.ncbi.nlm.nih.gov/pubmed/28018599
http://dx.doi.org/10.1186/s40425-016-0193-2

Ejemplares similares